scholarly journals Incidence of Erectile Dysfunction in Patients of Diabetes Mellitus

Author(s):  
Yar Muhammad Tunio ◽  
Ruqayya Farhad ◽  
Abdul Ghaffar Dars ◽  
Ghullam Mustafa Mangrio ◽  
Ummama Laghari ◽  
...  

Aim: The goal of this study was to determine how frequent erectile dysfunction is in diabetic people and what factors contribute to this condition. Methods:  In this study, type-2 diabetes patients were selected among outpatients who visited Diabetes Clinics regularly. For the first selection of patients, it was essential to have had a diagnosis of type 2 diabetes for at least six months but no more than 10 years. 1,080 male diabetic patients (with or without active ED symptoms) who visited the institute's Medicine or Psychiatry Outpatient Departments were included in the study throughout the period under consideration. The individuals' body mass index (BMI), blood sugar levels, and lipid profile were all measured. Erectile dysfunction became more common as people became older. ED was shown to be associated with elevated hemoglobin A1c (HbA1c), as well as hypertension, atherogenic dyslipidemia (low HDL-cholesterol and high triglycerides), metabolic syndrome, and depression in the study population. Male erectile dysfunction (ED) has been demonstrated to be prevented by physical activity, with men who exercised more being 10 percent less likely to develop ED than those who did not.  Results: Erectile dysfunction was shown to be prevalent in 32.21 percent of men. Patients with erectile dysfunction had a substantially higher mean age (58.4010.96 years) than those who did not have erectile dysfunction (51.0011.16 years) (p0.001). Conclusion: In conclusion, glycemic control and other metabolic variables were linked to ED risk in people with type 2 diabetes, having a greater degree of physical activity was protective.

2019 ◽  
Vol 26 (09) ◽  
pp. 1471-1476
Author(s):  
Shahzad Alam Khan ◽  
Iqra Imtiaz

Background: HDL particles have several biological functions. Low levels of HDL-cholesterol are responsible for atherosclerotic disease. Type 2 diabetes is a metabolic disease of chronic etiology and low HDL‐cholesterol is frequent finding in diabetics. Levels of HDL with advancing age are inconsistent, few study show decline in HDL with increasing age while others show vice versa results. Objectives: Objective of this study was to establish an association between low HDL levels with advancing age in type 2 diabetic patients. Study Design: Cross sectional descriptive study. Setting: Diabetes Outpatient Department Nishtar Hospital Multan. Period: 6 months extending from March 2018 to August 2018. Materials and Methods: 145 patients with newly or previously diagnosed type 2 diabetes mellitus, age >35 years were considered for the study. Those diabetics who had family history of dyslipidemias (to rule out familial hyperlipidemias) were excluded. Study was started after acquiring permission from ethical committee. All the patients were evaluated for the HDL levels by getting a fasting lipid assay. Results: Out of 145 cases 78 (53.6%) were males while remaining 67 (46.4%) were female. Mean age of the patients was 57.27 + 6.91 years. Mean HDL level was 37.82 + 8.42. It was seen that HDL is low in 116/145 (80%) patients. Those diabetic patients who were < 60 (91 cases), HDL was noticed to be low in 67/91(73.62%) patients. Among patients >60 years (54 cases), HDL was identified to be low in 49/54(90.7%) patients. P-value was found out to be 0.012 Conclusion: Due to falling levels of HDL with advancing age in diabetic patients, there is increase in cardiovascular events in elderly diabetic patients. So the measures which tend to increase HDL level will also give protection against adverse cardiovascular event in elderly diabetics.


2019 ◽  
Vol 12 ◽  
pp. 117955141986681 ◽  
Author(s):  
Yuka Kamijo ◽  
Hideto Ishii ◽  
Tomohiko Yamamoto ◽  
Kunihisa Kobayashi ◽  
Hiroyuki Asano ◽  
...  

Introduction: Recently, the sodium-glucose cotransporter2 (SGLT2) inhibitor empagliflozin has been shown to lower cardiovascular risk among diabetic patients. It is intriguing that some SGLT2 inhibitors have been found to increase low-density lipoprotein (LDL) cholesterol levels, while the relevance to high-density lipoprotein (HDL) cholesterol is unknown. Although the inhibitory effect of SGLT2 inhibitors on glucose reabsorption may accelerate compensatory lipid metabolism and subsequently reduce body weight and affect the lipid profile, much remains unclear about this mechanism. Therefore, we conducted this study to investigate in detail how canagliflozin affects lipoprotein fractions including LDL and HDL subclasses. Materials and Methods: This study is a multicenter prospective study. The participants were patients with 22 type 2 diabetes (60.7 ± 11.6 years, 59.1% of men) who had HbA1c ⩾ 7.0% and consented to participate in the study. They were administered 100 mg canagliflozin orally once per day. Biochemistry test and cholesterol levels of 20 lipoprotein fractions (G1-G20) using high performance liquid chromatography methods were examined before and after 12 weeks of treatment period. Results: Significant decreases were observed in the participants’ body weight (69.7 to 67.9 kg, P < .001), systolic blood pressure (129.3 to 119.5 mm Hg, P < .01), and HbA1c (8.5% to 7.4%, P < .001). Cholesterol levels in the 20 lipoprotein fractions increased for very large HDL (G14, G15) and large HDL (G16) ( P < .05). Conclusions: Reduction in body weight, improvement of blood glucose levels, and increases in very large HDL and large HDL subclasses were observed after canagliflozin treatment. These beneficial changes might contribute to subsequent suppression of cardiovascular outcomes.


2020 ◽  
Vol 12 (1) ◽  
Author(s):  
Agete Tadewos Hirigo ◽  
Tesfaye Teshome

Abstract Background Patients with severe mental illness (SMI) are at increased risk of developing non-communicable diseases that could cause significantly lower life expectancy when compared to the general population. This study aimed to assess the magnitude and predictors of undiagnosed type-2 diabetes and hypertension among adult patients with SMI on antipsychotic treatments. Methods A hospital-based cross-sectional study was conducted on 237 psychiatric patients from January to June 2019 at Hawassa University Comprehensive Specialized Hospital, Hawassa, Southern Ethiopia. All relevant information was collected using a structured interviewer-administered questionnaire with a systematic random sampling technique. A total of 4–5 mL of overnight fasting venous blood was collected from each patient. Serum lipid profiles and fasting blood sugar (FBS) were measured using the A25™ BioSystem Random Access chemistry analyzer. To identify predictors of hyperglycemia and raised blood pressure, multiple linear regression analysis was done using SPSS version 23. Statistical significance was set at p value < 5%. Results From 247 patients with SMI approached, 237 (58.2% male and 41.8% females) were take part in the study giving a response rate of 95.9%. The overall 31.2% (95%CI: 24.1–37.6) and 27.8% (95%CI: 23.2–33.4) of patients had hyperglycemia and raised BP. The magnitude of prediabetes and type-2 diabetes was 24.9% (95%CI:19.4–30.4), and 6.3% (95% CI: 3.4–10.1), respectively. While the magnitude of prehypertension and hypertension was 23.2% (95%CI: 17.3–29.5) and 4.6% (95%CI: 2.1–8.0), respectively. In multiple linear regression analyses: age, HDL-cholesterol, physical activity and Triglyceride/HDL-cholesterol ratio were positively correlated with FBS. While, HDL-cholesterol, waist circumference, physical activity, total cholesterol/HDL-c ratio, and body mass index were positively correlated with systolic and diastolic blood pressures. Conclusion The findings indicate a need to assess blood glucose and blood pressure at baseline before the commencement of any antipsychotic therapy and during therapeutic follow up to manage any increasing trends. Moreover, close monitoring of patients with severe mental illness on antipsychotic therapy is exclusively recommended.


2011 ◽  
Vol 93 (1) ◽  
pp. e44-e48 ◽  
Author(s):  
Bruno Vergès ◽  
Laura Radu ◽  
Sabine Baillot-Rudoni ◽  
Marie-Claude Brindisi ◽  
Alix Poussier ◽  
...  

Folia Medica ◽  
2013 ◽  
Vol 55 (1) ◽  
pp. 55-63 ◽  
Author(s):  
Mitko D. Mitkov ◽  
Ivanka Y. Aleksandrova ◽  
Maria M. Orbetzova

Abstract Erectile dysfunction (ED) is the inability to develop and/or maintain an erection that is sufficient for satisfactory sexual intercourse. The prevalence of erectile dysfunction in diabetic men is 28-75%, this percentage rising with patient’s age and duration of diabetes. The aim of the present study was to investigate erectile dysfunction and quality of life in patients with type 2 diabetes mellitus (T2DM) after treating them with transdermal testosterone or with alpha-lipoic acid. Materials and methods: The effect of a 12-week treatment with transdermal testosterone or alpha-lipoic acid on the erectile function and quality of life of 45 men with ED and T2DM was studied in a randomized, prospective, open clinical, comparative study. The parameters we measured in the patients were body weight and body mass index (BMI); the albumin, lipids, HbA1C, testosterone (T), sex hormone-binding globulin (SHBG), follicle stimulating hormone (FSH), luteinizing hormone (LH) and microalbuminuria levels; the International Index of Erectile Function (IIEF) and Health related quality of life (SF-36) questionnaires were completed to evaluate ED and quality of life before and after 12 weeks of treatment with alpha-lipoic acid (600 mg, parenterally, for 7 days, followed by 600 mg received per os) or with transdermal testosterone in a dose of 50 mg daily. Results: Testosterone treatment decreased BMI significantly (p < 0.01), increased testosterone concentrations (p < 0.01) and raised the SHBG levels (p < 0.05), improved the glycemic control and lipid profile (total cholesterol, p < 0.05; HDL cholesterol, p < 0.05; triglycerides, p < 0.05). The patients treated with alpha-lipoic acid had their BMI (p < 0.01), HbA1C (p < 0.01), total cholesterol (p < 0.01), HDL-cholesterol (p < 0.01) and triglycerides (p < 0.01) significantly reduced. The indicators for ED in both groups were also statistically significantly improved. There was improvement for all patients’ self-assessment score for “physical functioning” (p = 0.001), for “role limitations due to physical health” (p < 0.001) and for “general health perception” (p = 0.021). Conclusions: Transdermal testosterone and alpha-lipoic acid have a tangible beneficial effect on erectile dysfunction and on metabolic disorders in T2DM patients and can be used to treat such patients.


Jurnal GIZIDO ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 57-62
Author(s):  
I Made Djendra ◽  
Muksin Made Pasambuna ◽  
Siani Pintan

The purpose of this study was to determine the relationship between diet and physical activity on blood sugar levels of Type 2 Diabetes Mellitus patients at Pancaran Kasih Hospital in Manado City and the results of this study can be used as input material for patients to be able to maintain their diet and regulate physical activity to control blood sugar levels remain at normal limits. Diabetes mellitus is a chronic condition where the body cannot or does not produce insulin optimally. The study design used was a type of observational study with a cross sectional approach to determine the relationship between risk factors and disease. In this study used 2 independent variables, namely diet and physical activity and the dependent variable Diabetes Mellitus. The method of taking samples is using purposive sampling in accordance with the proposed inclusion and exclusion criteria. The samples needed in this study were 41 people determined by the Slovin formula. From the results of this study note that eating patterns have a value of p = 0.00, p <0.05 which means there is a significant relationship with eating patterns with blood sugar levels of Type 2 Diabetes Mellitus patients. Results of physical activity p = 0.03, p < 0.05 which means there is a significant relationship between physical activity and blood sugar levels in Type 2 Diabetes Mellitus patients at Pancaran Kasih Hospital in Manado City.


2020 ◽  
Vol 35 (4) ◽  
Author(s):  
Abdullah Mazhar ◽  
Tayyaba gul Malik ◽  
Aalia Ali ◽  
Hina Nadeem

Objectives: To find out a relationship of diabetic retinopathy with ankle-brachial (ABI) in patients of type 2 diabetes. Material and Methods It was a cross-sectional observational study carried out in Arif Memorial Teaching hospital and Rashid Latif Medical College from January 2019 to June 2019. 120 patients were selected by purposive convenient sampling from outpatient department of Arif Memorial Teaching hospital. After clinical history, complete ocular examination was performed. Random blood sugar levels were measured using Glucometer. Ankle-brachial index was calculated by dividing the systolic pressure at ankle by the systolic blood pressure at arm. Statistical analysis was done using SPSS 25. Independent sample t test and chi square tests were used to find out the significance of the results. Results: In this study of 120 diabetic patients, 80 (66.7%) were female and 40 (33.3%) were males. Mean Ankle Branchial Index (ABI) of Males was 0.96±0.11 and for females was 0.97±0.14. Among 120 participants of this study, 73 (60.83 %) patients had no signs of diabetic retinopathy, 35 (29.16 %) patients had NPDR and 12 (10%) patients had PDR. ABI was not associated with gender and duration of diabetes. However, there was negative and weak linear relationship between BSR and ABI (r= -0.221). This correlation was higher in diabetics of less than 5 year duration (r=-0.286) than in patients of more than 5 years duration of diabetes (r=-0.129).  Conclusion: Our study indicates that ABI is not significantly related with diabetic retinopathy. However, there is a positive relationship of ABI with high blood sugar levels.


2020 ◽  
Vol 315 ◽  
pp. e73
Author(s):  
K.C.B. Tan ◽  
A.C.H. Lee ◽  
Y. Wong ◽  
S.W.M. Shiu

Sign in / Sign up

Export Citation Format

Share Document